Statements (52)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:purple_toe_syndrome
|
gptkbp:affects |
blood vessels
|
gptkbp:associated_with |
gptkb:musician
gptkb:Raynaud's_phenomenon thrombosis chronic inflammatory response |
gptkbp:caused_by |
tobacco use
|
gptkbp:clinical_trial |
ongoing research
investigating new therapies studying disease mechanisms |
gptkbp:complications |
amputation
|
gptkbp:distribution |
more common in Asia and the Middle East
|
gptkbp:first_described_by |
Leo Buerger
|
gptkbp:historical_significance |
influenced vascular medicine
named after Leo Buerger recognized in the early 20th century |
https://www.w3.org/2000/01/rdf-schema#label |
Buerger's disease
|
gptkbp:is_known_for |
thromboangiitis obliterans
|
gptkbp:is_popular_in |
more common in men
typically diagnosed in young adults |
gptkbp:is_protected_by |
quitting smoking
managing stress avoiding tobacco products |
gptkbp:research_focus |
risk factors
treatment options pathophysiology |
gptkbp:risk_factor |
smoking
genetic predisposition autoimmune conditions |
gptkbp:social_responsibility |
ultrasound
biopsy clinical examination angiography more prevalent in certain ethnic groups rare in non-smokers |
gptkbp:symptoms |
numbness
gangrene tingling pain in limbs cold sensitivity ulcers on fingers |
gptkbp:treatment |
gptkb:hospital
stem cell therapy medications physical therapy anticoagulants pain management smoking cessation hyperbaric oxygen therapy vasodilators |